Addex Therapeutics Reports Positive Preclinical Data for GABAB PAM in Chronic Cough Model
Summary
Addex Therapeutics announced encouraging preclinical data for its GABAB PAM candidate, demonstrating robust anti-tussive activity and improved lung pathology in a chronic cough model, building on previous positive non-human primate data.
Key Events
-
Positive Preclinical Data
Addex Therapeutics announced encouraging preclinical data for its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model.
-
Robust Anti-Tussive Efficacy
The GABAB PAM candidate demonstrated robust and sustained anti-tussive efficacy, significantly reducing cough frequency and increasing cough latency over the treatment period.
-
Improved Lung Pathology and Safety
Studies showed improved lung pathology outcomes, including lower Ashcroft scores and reduced affected lung tissue, alongside a favorable safety profile with no meaningful changes in respiratory rate or body temperature.
-
Builds on Prior Positive Results
This data follows previous announcements of robust anti-tussive activity in non-human primate studies, further supporting the therapeutic potential for chronic cough management.
Analysis
This positive preclinical data for Addex Therapeutics' GABAB PAM candidate is a significant step forward for the company, particularly given the substantial unmet medical need in chronic cough, especially for patients with idiopathic pulmonary fibrosis (IPF). The demonstration of robust efficacy, improved lung pathology, and a favorable safety profile in a relevant disease model strengthens the therapeutic promise of this novel approach. This news, following earlier positive non-human primate data, provides further validation for the program and could attract potential partners or facilitate future clinical development, which is crucial for a clinical-stage biopharmaceutical company with a small market capitalization.
At the time of this filing, ADXN was trading at $6.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $5.41 to $12.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.